Australia markets closed

AbCellera Biologics Inc. (ABCL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.2600+0.1600 (+5.16%)
At close: 04:00PM EDT
3.2300 -0.03 (-0.92%)
After hours: 07:42PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 958.62M
Enterprise value 334.20M
Trailing P/E 19.92
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)26.45
Price/book (mrq)0.85
Enterprise value/revenue 9.34
Enterprise value/EBITDA 5.30

Trading information

Stock price history

Beta (5Y monthly) 0.39
52-week change 3-57.83%
S&P500 52-week change 318.96%
52-week high 37.8500
52-week low 32.6500
50-day moving average 33.3066
200-day moving average 34.3613

Share statistics

Avg vol (3-month) 31.66M
Avg vol (10-day) 31.14M
Shares outstanding 5294.05M
Implied shares outstanding 6294.05M
Float 8188.28M
% held by insiders 128.00%
% held by institutions 143.45%
Shares short (15 July 2024) 417.77M
Short ratio (15 July 2024) 48.24
Short % of float (15 July 2024) 47.85%
Short % of shares outstanding (15 July 2024) 46.04%
Shares short (prior month 14 June 2024) 419.72M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-551.48%

Management effectiveness

Return on assets (ttm)-9.59%
Return on equity (ttm)-12.56%

Income statement

Revenue (ttm)35.79M
Revenue per share (ttm)0.12
Quarterly revenue growth (yoy)-18.40%
Gross profit (ttm)N/A
EBITDA -203.5M
Net income avi to common (ttm)-146.9M
Diluted EPS (ttm)-0.5100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)698.02M
Total cash per share (mrq)2.37
Total debt (mrq)73.61M
Total debt/equity (mrq)6.52%
Current ratio (mrq)7.76
Book value per share (mrq)3.85

Cash flow statement

Operating cash flow (ttm)-41.52M
Levered free cash flow (ttm)-88.16M